Phaseline

Companies › InventisBio

InventisBio: clinical trials, targets and expected readouts

3 active drug programs in 13 registered trials: 5 Phase 2, 5 Phase 1, 3 Phase 3; Oncology, Gastroenterology, Genitourinary, Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
[14C] D-2570
TYK2 pseudokinase domain inhibitor
TYK2Phase 3Plaque Psoriasis; UC - Ulcerative Colitis; Psoriasis; PsA (Psoriatic Arthritis) …Nov 2026
D-0502–Phase 3Breast CancerNov 2026
D-1553
KRAS G12C inhibitor
KRASPhase 1Solid TumorDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07411742[14C] D-2570Phase 1Mass Balance StudyOtherMar 2026
NCT07270783[14C] D-2570Phase 1Healthy VolunteerOtherNov 2026
NCT07715175[14C] D-2570Phase 1Renal ImpairmentGenitourinaryNov 2026
NCT06954961D-0502Phase 3Breast CancerOncologyNov 2026
NCT07715149[14C] D-2570Phase 1Healthy Adult ParticipantsGastroenterologyNov 2026
NCT07035041[14C] D-2570Phase 2UC - Ulcerative ColitisImmunologyDec 2026
NCT07326813[14C] D-2570Phase 3Plaque PsoriasisImmunologyJul 2027
NCT07130604[14C] D-2570Phase 3Plaque PsoriasisImmunologyJul 2027
NCT07489885[14C] D-2570Phase 2PsoriasisImmunologyAug 2027
NCT07315061[14C] D-2570Phase 2PsA (Psoriatic Arthritis)ImmunologyAug 2027
NCT07625891[14C] D-2570Phase 2VitiligoImmunologyNov 2027
NCT05379946D-1553Phase 1Solid TumorOncologyDec 2027
NCT07311200[14C] D-2570Phase 2Active Systemic Lupus ErythematosusImmunologyAug 2028

Targets

TYK2 (1) KRAS (1)

Companies with the same targets

Revolution Medicines Bristol-Myers Squibb Incyte TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Roche Eli Lilly AbbVie Pfizer Amgen

Companies built like this

Ranok Therapeutics (Hangzhou) Blueprint Medicines SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany Genfleet Therapeutics (Shanghai) Chengdu Zenitar Biomedical Technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.